Received Feb 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Pain; swelling; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included mucinous carcinoma. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pain (Verbatim: Pain) and swelling (Verbatim: swelling). The outcome of the pain and swelling were not reported. It was unknown if the reporter considered the pain and swelling to be related to Shingrix. It was unknown if the company considered the pain and swelling to be related to Shingrix. Additional Information: GSK Receipt Date: 20-FEB-2025 Patient asked if they can take Shingrix while being treated for mucinous carcinoma. Patient had the first shot the day before diagnosis and had pain, swelling , etc
Mucinous carcinoma